Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Haematologica
Prif Awduron: Brown, Jennifer R., Harb, Wael A., Hill, Brian T., Gabrilove, Janice, Sharman, Jeff P., Schreeder, Marshall T., Barr, Paul M., Foran, James M., Miller, Thomas P., Burger, Jan A., Kelly, Kevin R., Mahadevan, Daruka, Ma, Shuo, Li, Yan, Pierce, Daniel W., Barnett, Evelyn, Marine, Jeffrey, Miranda, Monika, Azaryan, Ada, Yu, Xujie, Nava-Parada, Pilar, Mei, Jay, Kipps, Thomas J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Ferrata Storti Foundation 2016
Pynciau:
Online Only Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5004476/
https://ncbi.nlm.nih.gov/pubmed/27151992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.140806
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg